Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs

Journal of Veterinary Internal Medicine

Volumn 22, Issue 4, 2008, Pages 985-988

  Isotani, M ^a   Ishida, N ^a   Tominaga, M ^a   Tamura, K ^a   Yagihara, H ^a   Ochi, S ^b,c   Kato, R ^d   Kobayashi, T ^e   Fujita, M ^a   Fujino, Y ^a   Setoguchi, A ^f,g   Ono, K ^a   Washizu, T ^a   Bonkobara, Makoto ^a,b  

^a Department of Veterinary Clinical Pathology ^*

^b NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^c Satte General Hospital   (Japan)

^d Lion Animal Hospital   (Japan)

^e Japan Small Animal Cancer Center   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

c Kit; Dog; Gleevec; Mast cell tumor; Mutation

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ANTAGONISM; FEMALE; GENETICS; MALE; MUTATION; NUCLEOTIDE SEQUENCE; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DOG DISEASES; DOGS; FEMALE; MALE; MAST-CELL SARCOMA; MUTATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 47849096884     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.00132.x     Document Type: Article

References (20)

1. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002;38(Suppl 5):28-36.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
4. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
5. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002;39:529-535.
6. Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-1723.
7. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al. The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111.
8. Ma Y, Longley BJ, Wang X, et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 1999;112:165-170.
9. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002;100:585-593.
10. Kobie K, Kawabata M, Hioki K, et al. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Res Vet Sci 2007;82:239-241.
11. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768.
12. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
13. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
15. Patnaik AK, Ehler W, MacEwan G. Canine cutaneous mast cell tumor: Morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
16. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: Inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-5734.
17. Bonkobara M, Zukas PK, Shikano S, et al. Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. J Immunol 2001;167:6893-6900.
18. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
19. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-3096.
20. Lahortiga I, Akin C, Cools J, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008;93:49-56.